

Current Position: Professor of Neurology
Departments of Neurology and Neurosurgery
University of Colorado School of Medicine

Work Address: University of Colorado Anschutz Medical Campus
Academic Office 1
12631 E 17th Ave, Mailstop B-185
Room L15-5221
Aurora, CO 80045
Phone: 303-724-2184
Fax: 303-724-2213
E-mail: Denise.Damek@CUAnschutz.edu

Family: Married to Matthew Odle, daughters Rachel and Sarah

Education: 1984-1988 B.S. Chemistry, University of Texas at Austin, Austin, TX
1983 & 1985 Summer courses, Lee College, Baytown, TX
1988-1992 M.D., University of Texas Medical School at Houston, Houston, TX
1992-1993 Internal Medicine Internship, Mayo Graduate School of Medicine,
Rochester, MN
1993-1996 Residency in Neurology, Mayo Graduate School of Medicine,
Rochester, MN
1996-1998 Fellowship in Neuro-Oncology, Massachusetts General
Hospital/Harvard Medical School, Boston, MA

Academic Appointments:

1998-2006 Assistant Professor, Department of Neurology, University of Colorado School of
Medicine, Aurora, CO
2001-2006 Assistant Professor, Department of Neurosurgery, University of Colorado
School of Medicine, Aurora, CO
2006-2022 Associate Professor, Departments of Neurology and Neurosurgery, University
of Colorado School of Medicine, Aurora, CO
2022-Present Professor, Departments of Neurology and Neurosurgery, University of Colorado
School of Medicine, Aurora, CO
2013-Present Director, Neuro-Oncology Fellowship Program, University of Colorado School of
Medicine, Aurora, CO
2014-Present Director Neuro-Oncology Research Program, University of Colorado Cancer
Center
2015-Present Co-Director Adult Brain Tumor Program, University of Colorado

Other Professional Positions:

2010-2012 Avastin Glioblastoma Regional Advisory Board member, Genentech USA, Inc.
2013-2015 NovoCure Glioblastoma (GBM) Advisory Board Member, NovoCure, Inc.
2015-2017 NovoCure Consultant Expert User Group NovoTAL Mapping, NovoCure, Inc.

Honors, Special Recognitions and Awards:

1992 Alpha Omega Alpha Medical Honor Society
2007 Awarded Honorable Mention; Rubinstein Award for best paper on neuro-oncology
presented at the annual meeting of American Association of Neuropathologists:
Kleinschmidt-Demasters BK, Damek DM, Dogan A, Giannini C. EBV-driven CNS
lymphomas (PCNSLs) are seen in elderly patients on a variety of immunosuppressive
drugs for a variety of autoimmune/collagen vascular diseases. Poster Board number

- C118, program 555.15. Presented April 29, 2007 at the AANP/ASIP/EB 2007 conference, Washington, DC, April 2007.
- 2015 Golden Stethoscope Award for Best Use of Physical Exam Skills. Foundations of Doctoring Curriculum. May 5, 2015.

Memberships in Professional Organizations:

- 1998-2012 Southwest Oncology Group Brain Working Group Member
 1998-Present University of Colorado Cancer Center Full Membership
 1998-Present National Cancer Institute Investigator
 1997-Present Society for Neuro-Oncology
 1993-Present American Academy of Neurology
 1991-Present Alpha Omega Alpha Medical Honor Society
 1999-Present University of Texas Ex-Students Association, Lifetime Member
 2000-Present University of Texas Medical School at Houston Ex-Students Association, Lifetime Member

Major Committee and Service Responsibilities:

- Institutional:**
- 1998-2003 University of Colorado Medical Student Advisor
 2008-Present University of Colorado Foundations of Doctoring Medical Student Preceptor
 2011-2012 Faculty Senate Neurology Department Representative
 2012-2014 Search committee/Candidate Interviewer for new faculty in Radiation-Oncology
 2012-2014 Search committee/Candidate Interviewer for new faculty in Neuroradiology
- Departmental:**
- 1998-2002 Resident Selection Committee, Department of Neurology
 1999-Present Neurology Resident Faculty Mentor
 2008-2022 Neurology Department Finance Committee
 2014-Present Director (multiple years) and Lecturer, Resident Education Neuro-Oncology Didactic Block Director
 2013-Present Neuro-Oncology Fellowship Director
 2016-Present Neurology Department Outpatient Clinical Affairs Committee
 2016-2017 Neurology Department Wellness Committee
 2018-Present Neurology Department APP Promotion Committee
 2020-Present Neurology Department Wellness Committee
- Hospital:**
- 1998-2002 Cancer Steering Committee, University of Colorado Cancer Center
 1998-Present Protocol Review and Monitoring Committee, University of Colorado Cancer Center
 1998-Present Cancer Center Committee, University of Colorado Cancer Center
 2000-2004 Planning Committee, Biannual Team up for Triumph Brain Tumor Conference
 2002-Present Neuro-Oncology Clinical Trials Disease Chairman
 2012-2014 EPIC After Visit Summary Committee Member
 2013-Present Neuro-Oncology Beacon Protocol Validation Chair
 2013-Present Neuro-Oncology Clinical Research Chairman
 2013-Present Protocol Review and Monitoring System Executive Committee
 2014-Present Director Neuro-Oncology Research Program
 2015-Present Co-Director Adult Brain Tumor Program

National:	2002	Planning committee, National Brain Tumor Foundation Brain Tumor Conference, Denver Site
	2010-present	Physician Evaluator. Center for Personalized Education for Physicians (CPEP) Practice Monitoring Program's Competence Assessment and Reentry to Clinical Practice programs.
	2014-present	SNO Fellowship Director Committee
	2018-present	SNO Women in Neuro-oncology Committee
	2018-present	AACR-NovoCure Tumor Treating Fields Research Grants Scientific Review Committee
	2019-present.	AAN Abstract Reviewer
	2020-2021	SNO Women in Neuro-oncology Group Mentor in pilot mentoring program

Community: Catholic Church, Denver, CO	2003-2012	Advisory Board, Nursing Ministry, Blessed Sacrament
	2008-2015	Grants Committee Chair, Blessed Sacrament Catholic School, Denver, CO
	2010-Present	Guest Lecturer, 1 day/year for 2 classes on medicine topics, Blessed Sacrament Catholic School and Good Shepherd Catholic School, Denver, CO
	2012-Present	Science Fair Judge, grades 5-8, 1-2 schools/year Archdiocese of Denver Catholic Schools
	2015-Present	Qualified Scientist, Science Fair Mentoring Program, Good Shepherd Catholic School, Denver, CO

Licensure and Board Certification:

1993-1998	Minnesota Licensure (currently inactive), Minnesota State Board of Medical Examiners
1997	Board Certification in Neurology, American Board of Psychiatry and Neurology
1998-Present	Colorado Licensure, Colorado State Board of Medical Examiners
2007	Board Recertification in Neurology, American Board of Psychiatry and Neurology
2008	Subspecialty Certification in Neuro-Oncology, United Council for Neurologic Subspecialties
2017	Board Recertification (Maintenance of Certification), American Board of Psychiatry and Neurology
2017-2028	Subspecialty Recertification for Neuro-oncology, United Council for Neurologic Subspecialties

Review and Referee Work:

2011-Present	Ad Hoc Reviewer: American Academy of Neurology Practice Guidelines
2011-Present	Ad Hoc Reviewer: Neurology
2013-Present	Ad Hoc Reviewer: British Medical Journal
2014-Present	Ad Hoc Reviewer: Neuroscience
2015-Present	Ad Hoc Reviewer: Journal of Nuclear Medicine, Radiology & Radiation Therapy
2016-Present	Ad Hoc Reviewer: British Medical Journal of Neurology
2017-Present	Ad Hoc Reviewer: Neuro-Oncology
2018-Present	Ad Hoc Reviewer: Journal of Clinical Oncology
2018-Present	Ad Hoc Reviewer: JAMA Oncology

Invited Extramural Lectures and Presentations:

1. Guest Lecturer: Neurology Grand Rounds. University of Utah Health Sciences Center, Salt Lake City, UT. CNS Lymphoma. February 1998.
2. Guest Lecturer: Neurology Grand Rounds. University of Colorado Health Sciences Center, Denver, CO. CNS Lymphoma. March 1998.
3. Course Speaker: 2nd Annual Neurology Update for the Neurologist. The Givens Institute of the University of Colorado, Aspen, CO. The Latest in Neuro-Oncology. July 9, 1999.
4. Course Speaker and Panel Discussion Leader: Team up for Triumph Brain Tumor Conference. Arvada, CO. Chemotherapy and the treatment of brain tumors. May 5, 2000.
5. Lecturer: Cancer Support Group. Blessed Sacrament Catholic Church, Denver, CO. Complementary medicine and the cancer patient. June 2000.
6. Guest Lecturer: Denver Oncology Nursing Society Meeting. Denver, CO. Clinical Neuro-Oncology. September 19, 2001.
7. Lecturer: Schering Oncology Biotech sponsored dinner meeting. Treatment of brain metastases in non-small cell lung cancer. Denver, CO. June 2002.
8. Platform Speaker: National Brain Tumor Foundation 7th National Brain Tumor Conference. Connecting in the Present, Looking Toward the Future. Denver, CO. Video-conferenced lecture: Clinical trials in the treatment of brain tumors. September 21, 2002.
9. Breakout Session Speaker: National Brain Tumor Foundation 7th National Brain Tumor Conference. Connecting in the Present, Looking Toward the Future. Denver, CO. Recurrence: What you need to know. September 21, 2002.
10. Breakout Session Speaker: National Brain Tumor Foundation 7th National Brain Tumor Conference. Connecting in the Present, Looking Toward the Future. Denver, CO. Chemotherapy: Managing side effects. September 21, 2002.
11. Breakout Session Speaker: National Brain Tumor Foundation 7th National Brain Tumor Conference. Connecting in the Present, Looking Toward the Future. Denver, CO. Long-term treatment issues. September 21, 2002.
12. Guest Lecturer: Pikes Peak Oncology Nursing Society Meeting. Boulder, CO. Nursing issues in Neuro-Oncology. June 19, 2003.
13. Guest Lecturer: St. Mary's Hospital. Determining Treatment Response in Malignant Gliomas: The Impact of Pseudoprogression and Pseudoresponse. Grand Junction, CO. August 5, 2010.
14. Invited Speaker: American Brain Tumor Association (ABTA) Partners in Treatment and Care. Patient and Care Giver Meeting. Managing Fatigue. May 2, 2015.
15. Invited Speaker: American Brain Tumor Association (ABTA) Partners in Treatment and Care. Patient and Care Giver Meeting. Seizures, Brain Tumors, and You. May 2, 2015.
16. Invited Speaker: Colorado Cancer Wellness Conference. Aurora, CO. Chemobrain – Managing Long Term Effects of Chemotherapy. September 19, 2015.
17. Invited Speaker: Prime Oncology. Denver, CO. Thinking Outside the Box in Glioblastoma: 2015 and Beyond. October 14, 2015.
18. Invited Speaker: CancerCon 2016. Denver, CO. ChemoBrain: It's a Real Thing. April 30, 2016.
19. Invited Speaker: New and Emerging Treatments for Brain Tumors. Brain Tumor Education Day. University of Colorado Hospital October 15, 2016.
20. Invited Speaker: Good Shepherd Catholic School 6th Grade Science Classes. Endocrinology of the Circus. Denver, CO. February 9, 2017.
21. Invited Speaker: Good Shepherd Catholic School 6th Grade Science Classes. Endocrinology of the Circus. Denver, CO. February 27, 2018.
22. Invited Speaker: Regis Jesuit High School Women in Science and Health. Aurora, CO. So you want to be a doctor? January 14, 2019.
23. Invited Speaker: Good Shepherd Catholic School 6th Grade Science Classes. Endocrinology of the Circus. Denver, CO. March 1, 2019.
24. Invited Speaker: 1st Neuro-Oncology Symposium Muhimbili Orthopaedic Institute, Dar es Salaam, Tanzania. July 29 – August 2, 2019. Epidemiology of Brain Tumors.
25. Invited Speaker: 1st Neuro-Oncology Symposium Muhimbili Orthopaedic Institute, Dar es Salaam, Tanzania. July 29 – August 2, 2019. Molecular Pathways in Brain Metastases.
26. Invited Speaker: 1st Neuro-Oncology Symposium Muhimbili Orthopaedic Institute, Dar es Salaam, Tanzania. July 29 – August 2, 2019. Chemotherapy Management of Meningiomas.

27. Invited Speaker: 1st Neuro-Oncology Symposium Muhimbili Orthopaedic Institute, Dar es Salaam, Tanzania. July 29 – August 2, 2019. Systemic Treatment Options for Brain Metastases.
28. Invited Speaker: 1st Neuro-Oncology Symposium Muhimbili Orthopaedic Institute, Dar es Salaam, Tanzania. July 29 – August 2, 2019. Juvenile Pilocytic Astrocytomas.
29. Invited Speaker: 1st Neuro-Oncology Symposium Muhimbili Orthopaedic Institute, Dar es Salaam, Tanzania. July 29 – August 2, 2019. Diffuse Midline Gliomas.
30. Invited Speaker: 1st Neuro-Oncology Symposium Muhimbili Orthopaedic Institute, Dar es Salaam, Tanzania. July 29 – August 2, 2019. Seizure Management in Brain Tumor Patients.
31. Invited Speaker: 16th Annual Symposium Justin Parker Neurological Institute: Current Techniques in the Treatment of Cranial and Spinal Disorders. Omni Interlocken Resort. Broomfield, CO. Leveraging Physics to Fight Cancer: The Role of Optune in Brain Tumor Treatment. November 2, 2019.

Intramural Lectures and Presentations (Excludes Didactic Medical Student/Resident Lectures):

1. Lecturer: University of Colorado Cancer Center Brain Tumor Support Group. Complementary Therapy in the Brain Tumor Patient. November 1998.
2. Lecturer: Neurology Grand Rounds, University of Colorado. Recurrent Malignant Gliomas. January 1999.
3. Lecturer: Neurology Grand Rounds, University of Colorado. Neurotoxicity of Radiation Therapy: November 1999.
4. Lecturer: University of Colorado Cancer Center Brain Tumor Support Group. New Treatments for Brain Tumors, May 2000.
5. Discussant: Clinicopathologic Conference. Denver Veterans Administration Medical Center, Denver, CO. May 2000.
6. Lecturer: Neurology Grand Rounds, University of Colorado. Neurolymphomatosis. December 2000.
7. Course Speaker: Clinical Oncology Nursing Seminar, University of Colorado: Clinical Neuro-Oncology. May 23, 2001.
8. Lecturer: Neurology Grand Rounds, University of Colorado. Brain Metastases. July 2002.
9. Course Speaker: Advanced Concepts in Neuroscience Nursing Symposium. University of Colorado Hospital. Neuro-Oncology. May 28, 2003.
10. Lecturer: Neurology Grand Rounds, University of Colorado, Meningiomas: When a good tumor goes bad. July 2003.
11. Lecturer: Neurology Grand Rounds, University of Colorado. Paraneoplastic Retinopathy/Optic Neuropathy. July 2004.
12. Lecturer: University of Colorado Cancer Center Brain Tumor Support Group. Getting the Most out of your Physician Visits. August 2004.
13. Lecturer: University of Colorado Cancer Center Brain Tumor Support Group. Understanding the Genetics of Brain Tumors. June 2005.
14. Lecturer: Neurology Grand Rounds, University of Colorado. When a Brain Tumor is not Really a Tumor. February 2006.
15. Lecturer: University of Colorado Cancer Center Brain Tumor Support Group. Brain Tumor Treatment Update. November 2006.
16. Discussant: Clinicopathologic Conference. Denver Veterans Administration Medical Center, Denver, CO. February 9, 2007.
17. Lecturer: Neurology Grand Rounds, University of Colorado. To be or not to be a Brain Tumor. May 30, 2007.
18. Lecturer: Neurology Grand Rounds, University of Colorado. Bilateral subdural hematomas post lumbar puncture in a 24-year-old female. December 3, 2008.
19. Lecturer and Discussion Leader: CU Women's Succeeding Symposium. Collaborative Peer Mentoring Groups: An Alternative to Traditional Dyadic Mentoring. March 6, 2009. Presented by Denise Damek, MD, Lauren Frey, MD, Yvonne Rollins, MD PhD, and Laura Strom, MD.
20. Lecturer: Neurology Grand Rounds, University of Colorado. A 60-year-old woman with three known systemic malignancies and perivascular lesion on brain imaging of unknown significance. Presented by Bette K DeMasters, MD and Denise M Damek, MD. September 1, 2010.

21. Lecturer: Neurology Grand Rounds, University of Colorado. Pseudoprogression and Pseudoresponse in the Treatment of Malignant Gliomas. September 1, 2010.
22. Lecturer: Neurology Grand Rounds, University of Colorado. Spectrum of Venous Abnormalities in Cancer Patients. January 18, 2012.
23. Lecturer: Neurology Grand Rounds, University of Colorado. Field of Dreams: A novel treatment for recurrent glioblastoma. May 22, 2013.
24. Lecture preparation assistance (group format presentation with Neuromuscular Division and Neuro-Oncology Division): Neurology Grand Rounds, University of Colorado. Detecting and treating depression in progressing neurological disorders. August 14, 2013.
25. Lecturer: Wellness Lecture Series, Cancer Center Support Programs and Resources. Cognitive Effects of Chemotherapy. Anschutz Inpatient Pavilion Conference Center. September 10, 2014.
26. Lecturer: Neurology Grand Rounds, University of Colorado. Opioids for Chronic Non-Cancer Pain: A Prescription for Change. January 14, 2015.
27. Lecturer: Neurology Grand Rounds, University of Colorado. Gadolinium Enhancement or Diminishing Returns? October 7, 2015.
28. Lecturer: Neurology Grand Rounds, University of Colorado. Controversies in the Management of Lymphomatous Meningitis. February 10, 2016.
29. Lecturer: Neurology Grand Rounds, University of Colorado. The Ambiguity of Benignity. March 1, 2017.
30. Lecturer: University of Colorado Cancer Center Brain Tumor Support Group. Practical Significance of Genetic Marker in Brain Tumors. February 7, 2018.
31. Lecturer: Cancer Center Education Work Group Lunch-and-Learn. Brain Tumors 101. January 15, 2020.
32. Lecturer: Neurology Grand Rounds, University of Colorado. Breaking Bad News. March 4, 2020.
33. Lecturer: Neurology Grand Rounds, University of Colorado. New Treatment Paradigms in Neurofibromatosis Type I. April 28, 2021.
34. Lecturer: Neurology Grand Rounds, University of Colorado. Getting SMART. February 9, 2022.

Teaching Activity:

Lectures, Seminars, Conferences:

Presentations to Medical Students:

- | | |
|--------------|----------------------------------------------------------------------------------------------------------------------------------|
| 1998-1999 | Faculty Facilitator: Neurology 7000. Medical Student Neurology Seminars. UCSOM. |
| 1999 | Lecturer: IDPT 6004. 2 nd Year Medical Student Clinical Neuroscience Course. Headache. UCSOM1999-2001 |
| | Lecturer: IDPT 6004. 2 nd Year Medical Student Clinical Neuroscience Course. CNS Tumors Demonstration. UCSOM1999-2004 |
| | Lecturer: IDPT 6004. 2 nd Year Medical Student Clinical Neuroscience Course. Neuro-Oncology. UCSOM |
| 2004-present | Faculty Facilitator: Foundations of Doctoring Phase I or II: Neurological Examination. UCSOM |

Presentations to House Officers:

- | | |
|--------------|---------------------------------------------------------------------------------------------------------------------------------|
| 1998-2004 | Faculty Facilitator: Neurology Resident Morning Report. 1-2 hours/year. UCSOM |
| 1999-2008 | Faculty Facilitator/Evaluator: Neurology Resident Mock Boards. 1-2 times/year. UCSOM |
| 1998-2011 | Lecturer: Neurology Resident Neurological Emergency Lecture Series. Neuro-Oncology Urgent Issues. |
| 1999-present | Faculty Facilitator: Journal Club, Department of Neurology Resident Conference. 8 discussion sessions total. |
| 1999-Present | Lecturer and Course Director (every other year): Neurology Resident Core Lecture Series. Neuro-Oncology topics. 2-8 hours/year. |
| 2005-2007 | Lecturer: Neurology Resident Neurological Emergency Lecture Series. Medical Documentation. UCSOM |

2021 Lecturer Radiation Oncology Resident Core Lecture Series

Presentations to Fellows:

2006 Lecturer: Medical Oncology Fellow Core Curriculum Clinical Series. Gliomas.
 2006 Lecturer: Medical Oncology Fellow Core Curriculum Clinical Series. Paraneoplastic Syndromes.
 2014-16 Discussant/Faculty Facilitator: Neuro-oncology Fellowship weekly educational seminar.
 2018-present Discussant/Faculty Facilitator: Neuro-oncology Fellowship weekly educational seminar.

Ward/Clinic Attending:

1998-2011 Attending. Neurology Inpatient Ward and Consult Services with supervision and bedside teaching of residents and students. 2 weeks to 14 weeks per year. University of Colorado Hospital and Denver Health Medical Center.
 1998-2003 Attending. Neuro-Oncology Outpatient Clinic with supervision and teaching of residents 4 hours/week. University of Colorado Hospital.
 1998 and 2003-2010 Attending. Neurology Resident Continuity Clinic with supervision and teaching of residents 4 hours/month. University of Colorado Hospital.
 1999-2002 Attending. Neurology Outpatient Clinics with supervision and teaching of medical students and residents 4-8 hours/week. Denver Health Medical Center.
 2004-present Attending. Neuro-Oncology Outpatient Clinics with supervision and teaching of medical oncology fellows 0-72 hours/year
 2008-present Attending. Neuro-Oncology Outpatient Clinics with supervision and teaching of 1-2 medical student(s) under the Foundations of Doctoring Program 8-16 hours/month, medical students as part of their Neurology clinical rotation 0-16 hours/month, internal medicine residents rotating through oncology clinics 0-12 hours/month, medical oncology fellows 0-16 hours/month.
 2009-present Attending. Neuro-Oncology Outpatient Clinics with supervision and teaching of neurology residents doing neuro-oncology electives. One month/year.
 2011-2017 Attending night call. Neurology Inpatient Ward and Consult Services with remote supervision of residents. One night per month per year.
 2014-16 Attending. Neuro-Oncology Outpatient Clinics with supervision and teaching of neuro-oncology fellow, 12-20 hours/week.
 2014-16 Attending. Neuro-Oncology Inpatient Consultations with supervision and teaching of neuro-oncology fellow, 0-4 hours/week.
 2015 Attending. Neurology Inpatient Ward and Consult Services with supervision and bedside teaching of residents and students. 2 weeks. University of Colorado Hospital.
 2018-present Attending. Neuro-Oncology Outpatient Clinics with supervision and teaching of neuro-oncology fellow, 12-20 hours/week.
 2018-present Attending. Neuro-Oncology Inpatient Consultations with supervision and teaching of neuro-oncology fellow, 0-4 hours/week.

Key Teaching Positions:

2008-present Preceptor. Foundations of Doctoring Program
 2013-present Neuro-Oncology Resident Education Block Director (every other year, alternating with Dr. Douglas Ney)

2013-present Neuro-Oncology Fellowship Director

Mentoring Record:

Secondary Students

- Qualified Scientist for the Good Shepherd Science Fair Mentoring Program impacting 6-8th grade students. 2015-present. Approximately 40 students each year advance to the Denver Metro Regional Science and Engineering Fair, and 1-2 students each year advance to the Colorado State Science Fair.

Undergraduate Students

- Summer 2012: Sarah Clark. I was Sarah's preceptor in the Cancer Research Fellowship Program. Sarah worked on a retrospective chart review and presented a poster at the completion of the program, as well as at the Society of Neuro-oncology Meeting in Washington, D.C in November 2012. She went on to attend medical school.
- 2016: Mariah Vigil. Summer Health Careers Institute June 2016. Colorado AHEC Program.
- 2019: Teddy Wroblewski. UCHHealth sponsor of student extended academic observation.
- 2019: William Foreman. UCHHealth sponsor of student extended academic observation.
- 2019: Samuel Scherer. UCHHealth sponsor of student extended academic observation.
- 2020: Katie Vaeth. Katie will graduate from St. Louis University double majoring in biology and mathematics in May 2021. She has been accepted into the Molecular Biology PhD program at the University of Colorado Anschutz Campus.

Medical Students

- 2008-2016: Tara Carlisle (formerly Martin), MD PhD. UCSOM Class of 2016. I mentored Tara through the Foundations of Doctoring course of the UCSOM. Tara matched in the Neurology Residency Program at Brigham's & Women's Boston, MA and is currently Neurobehavioral Fellow at UCSOM.
- 2011. Melissa Deloughry, MD. UCSOM Class of 2014. I mentored Melissa through the Foundations of Doctoring course of the UCSOM.
- 2012. Seerat Poonia, MD. UCSOM Class of 2015. I mentored Seerat through the Foundations of Doctoring course of the UCSOM. She was the 1st author of a patient case report.
- 2016-2018: Weston(Wes) Ryan, MD. UCSOM Class of 2019. I mentored Wes through the Foundations of Doctoring course of the UCSOM.
- 2018-present: Philip Tatman, MD PhD student at UCSOM. I am mentoring Phil through the Foundations of Doctoring course of the UCSOM, as well as clinical research advisor/mentor on grant funded projects through Meningioma Mommas which have yielded multiple peer-reviewed scientific abstracts and a submitted publication.

Residents

- I have mentored and guided many residents from the Department of Neurology, two of which have gone on to become neuro-oncology fellows, Alex Mohler, MD and Caroline Goldin, MD.

Fellows

- 2014-2016: Alex Mohler, MD. Alex went on to an academic neuro-oncology position at Brown University. During his fellowship, he authored one first author paper and was 1st author on two poster presentations at the Society of Neuro-oncology Annual Meeting.
- 2018-2020: Justin Goranovich, MD. Justin went on to an academic neuro-oncology position at Ohio State University Wexler Cancer Center.
- 2020-2022: Caroline Goldin, MD. Caroline is practicing at Ochsner Medical Center with an affiliate academic position at Louisiana State University School of Medicine.

Faculty

- Developed and led a neurology faculty peer mentoring group with 5 faculty from 2006-2010. We presented a presentation/workshop on our experience at the CU Women Succeeding Symposium in 2009.
- Selected as one of five individuals to be a mentor in the Society for Neuro-oncology Women and Diversity Facilitated Mentorship Pilot. October 2020-April 2021. Mentored four neuro-oncology junior faculty.
- Faculty advisor, Neuro-oncology Fellows in Training (NOFT) Journal Club 2020-2022.

Other Clinically-Related Activities:

1999	KCNC "Ask the Doctor" program on Neurological Disorders, March 18, 1999
2000	Neuro-Oncology Booth, CU School of Medicine Special Exhibits, 117 th Anniversary celebration; CU Medicine Ball (May 13, 2000)
2002	KCNC "Ask the Doctor" program on Stroke
2010	Denver Fox News Interview: Cell phone use and brain tumors.
2015	Quality Improvement Project: PHq9 Health Questionnaires in Brain Tumor Patients. QI project lead: Denise Damek, MD
2017	Quality Improvement Project: Improving Physician to Physician Communication by Increasing Rates of Referral Letters Sent to Referring Physicians. QI project lead: Jennifer Simpson, MD

Clinical Trials:**Active:****Principle Investigator:**

1. Principle Investigator. NCT02343406. COMIRB 15-0164. AbbVie. Protocol M14-483. INTELLANCE 2: ABT-414 alone or ABT-414 plus temozolomide Versus Lomustine or Temozolomide for recurrent glioblastoma: a randomized phase II study of the EORTC Brain Tumor Group. Direct Costs: \$131,230. Total Costs: \$165,350. Opened for accrual 3/8/2016-3/7/2021. Enrolled patients in follow-up.
2. Principle Investigator. NCT02152982. COMIRB 15-0398. Alliance A071102. Randomized Trial of Veliparib or Placebo in Combination with Adjuvant Temozolomide in Newly Diagnosed GBM with MGMT Promoter Hypermethylation. 1/1/2016-1/1/2018. Enrolled patients in follow-up.
3. Principle Investigator. NCT02414165. COMIRB 15-1752. Tocagen Inc. Tg511-15-01. A Phase 2/3 Randomized, Open-Label Study of Toca 511, a Retroviral Replicating Vector, Combined with Toca FC versus Standard of Care in Subjects Undergoing Planned Resection for Recurrent Glioblastoma or Anaplastic Astrocytoma (Toca 5). Direct Costs: \$129,700. Total Costs \$150,422. 7/7/2016-12/20/2020. Open for accrual 11/8/2016-12/1/2018. Enrolled patients in follow-up.
4. Principle Investigator. NCT02523014. COMIRB 15-1747. Alliance A071401. Phase II Trial of SMO/AKT/NF2 Inhibitors in Progressive meningiomas with SMO/AKT/NF2 mutations. Open to accrual. 1/1/2016-present.
5. Principle Investigator. NCT03522298. COMIRB 18-0376. Kazia Therapeutics. A phase 2a study to evaluate the safety, pharmacokinetics and clinical activity of the PI3K/mTOR inhibitor GDC-0084 administered to patients with glioblastoma multiforme characterized by unmethylated O6-methylguanine-methyltransferase promoter status. 6/15/2018-6/14/2023. Direct costs \$280,420. Total costs \$358,938. Enrolled patients in follow-up.
6. Principle Investigator. NCT03684811. COMIRB 18-2219. FORMA Therapeutics. Protocol 2101-ONC-102. A phase 1b/2 study of FT-2102 in patients with advanced CNS and solid tumors with an IDH1 mutation. Enrolled patients in follow-up.
7. Principle Investigator. NCT03970447. Global Coalition for Adaptive Research. GBM AGILE: Global adaptive trial master protocol. Direct Costs: \$236,390. Total Costs \$283,688. 6/3/2019-6/2/2024. May 2020-.
8. Principle Investigator. COMIRB 17-1974. Diffusion Pharmaceuticals. Open-label, randomized, controlled, phase 3 safety and efficacy study of Tran Sodium Crocetin (TSC) with radiation

therapy and temozolomide in newly diagnosed GBM biopsy-only subjects. 11/27/2017-11/26/2020. Sponsor hold for new protocol amendment.

9. Principle Investigator. COMIRB 20-2112. Novocure: EF-32 (TRIDENT): A Pivotal, Randomized, Open-label Study of Optune (TTFIELDS, 200KHz) Concomitant with Radiation Therapy and Temozolomide for the Treatment of Newly Diagnosed Glioblastoma. 8/18/2021-.
10. Principle Investigator. COMIRB 21-3021. Alliance A071702. Phase II study of checkpoint blockade immunotherapy in patients with somatically hypermutated recurrent glioblastoma. 9/13/2021-.

Sub-Investigator:

1. Sub-Investigator NCT04164901. COMIRB 19-2707. A Phase 3, Multicenter, Randomized, Double-blind, Placebo-Controlled Study of AG-881 in Subjects with Residual or Recurrent Grade 2 Glioma with an IDH1 or IDH2 Mutation (INDIGO). June 2020-.
2. Sub-Investigator NCT02796261. COMIRB 18-1336. A Phase 3, Randomized Open-Label Study to Evaluate the Efficacy and Safety of Eflornithine with Lomustine Compared to Lomustine Alone in Patients with Anaplastic Astrocytoma that Progress/Recur After Irradiation and Adjuvant Temozolomide Chemotherapy. STELLAR Study. January 2020-.
3. Sub-Investigator: NCT02465060. ECOG-ACRIN Cancer Research Group. Molecular Analysis for Therapy Choice (MATCH). August 2005-.
4. Sub-Investigator: NCT02568267. COMIRB 15-1574. Ignyta/Roche. GO40782 An Open-Label, Multicenter, Global Phase 2 Basket Study of Entrectinib for the Treatment of Patients with Locally Advanced or Metastatic Solid Tumors that Harbor NTRK1/2/3, ROS1, or ALK Gene Rearrangements. November 2015-.
5. Sub-Investigator COMIRB 16-0315. Exceptional Responders Pilot Study: Molecular profiling of tumors from cancer patients who are exceptional responders.
6. Sub-Investigator. NCT02146066. COMIRB 14-1876 Northwest Biotherapeutics. NWBT 0202EA (EAP) study. An Expanded Access Protocol for the Treatment of Glioblastoma Multiforme in Patients with Already Manufactured DCVax-L Autologous Dendritic Cells Pulsed with Tumor Lysate Antigen Who Have Screen-Failed Protocol 020221. Closed to accrual December 2016; following enrolled patients.
7. Co-investigator: Meningioma Mommas. Pre-clinical trial evaluation of HDAC inhibitors for the treatment of meningiomas. Specific Aim: We aim to verify if HDACs are efficacious targets for the treatment of meningiomas through the use of mouse models with romidepsin and other HDAC inhibitors. 2019-2020.
8. Sub-Investigator. NCT02796261. COMIRB 18-1336. Orbus Therapeutics. A Phase 3, Randomized, Open-Label Study To Evaluate the Efficacy and Safety of Eflornithine with Lomustine Compared to Lomustine Alone in Patients with Anaplastic Astrocytoma That Progress/Recur After Irradiation and Adjuvant Temozolomide Chemotherapy STELLAR Study. July 2016-.
9. Sub-Investigator. NCT03604978. COMIRB 19-0423 - A Phase I/II Study of Nivolumab Plus or Minus Ipilimumab in Combination with Multi-Fraction Stereotactic Radiosurgery for Recurrent High-Grade Radiation-Relapsed Meningioma. November 2018-.
10. Sub-Investigator. NCT02498951. COMIRB 16-1217. Maintenance Obinutuzumab for Primary Central Nervous System Lymphoma Complete Responders. July 2016-.
11. Sub-Investigator. COMIRB 20-2697. Denovo Biopharma: A Randomized, Double-Blind, Placebo-Controlled Phase 3 Study of Enzastaurin Added to Temozolomide During and Following Radiation Therapy in Newly Diagnosed Glioblastoma Patients Who Possess the Novel Genomic Biomarker DGM1.

Completed:

1. Principle Investigator. Integrated Therapeutics: Phase 2 treatment of adults with progressive or recurrent primary CNS lymphoma with Temodar®. 2000-2001. Total Direct Costs: \$7,549.

2. Principle Investigator. Integrated Therapeutics: Phase 2 treatment of adults with newly diagnosed, progressive, or recurrent primary malignant anaplastic oligodendroglioma with Temodar®. 2000-2001. Total Direct Costs: \$4,167.
3. Principle Investigator. Schering Plough P02143 (NCT00034697, COMIRB 01-398): A phase II study of temozolomide in subjects with brain metastasis from non-small cell lung cancer. November 2001-November 2004. Total Direct Costs \$25,259.
4. Sub-investigator. Xenova Biomedix Ltd (NCT00083447, COMIRB 03-524): A phase III multicenter study of intratumoral/interstitial therapy with TransMID™ compared to best standard of care in patients with progressive and/or recurrent, non-resectable glioblastoma multiforme. September 2004-September 2006. Total Direct Costs: \$220,275.
5. Principle Investigator. SkyPharma, Inc (SKY0101-010, NCT00029523): A randomized clinical study to determine the patient benefit and safety of Depocyt®(Cytarabine liposome injection) for the treatment of neoplastic meningitis. January 2002-February 2007. Total project direct costs: \$111,444.
6. Sub-investigator. AstraZenica (COMIRB 03-124): A Phase I Dose-Escalation Study of Fractionated Stereotactic Radiosurgery in Combination with Gefitinib in Patients With Recurrent Malignant Gliomas. June 2004-June 2007. Total Direct Costs: \$146,705.
7. Principle investigator. Neurobiological Technologies, Inc. NTI 0302 (NCT00226668, COMIRB 04-0214): A phase III randomized, double-blind study comparing human corticotropin-releasing factor (hCRF) to dexamethasone for control of symptoms associated with peritumoral brain edema in patients with primary malignant brain tumors. September 2004-September 2007. Total Direct Costs: \$64,895.
8. Principle Investigator. EMD Pharmaceuticals (NCT00093964, COMIRB 01-788): A multicenter, open-label, randomized, uncontrolled, phase IIa trial in subjects with recurrent glioblastoma multiforme to investigate the clinical activity, safety, and tolerability of EMD 121974 (cilengitide) administered as a single agent in doses of 500 mg and 2000 mg. February 2005-February 2008. Total Direct Costs: \$64,380.
9. Principle Investigator: 08-0151. AstraZeneca (NCT00777153): A Phase III, Randomized, Parallel Group, Multi-Center Study in recurrent Glioblastoma subjects to compare the efficacy of AZD2171 (RECENTIN) monotherapy and the combination of AZD2171 with Lomustine to the efficacy of Lomustine alone. 8/20/2008-8/20/2011. Direct Costs \$387,618. Total Costs \$387,618.
10. Sub-investigator. University of Colorado Cancer Center (NCT00792012, COMIRB 05-0562): A Phase I Dose Per Fraction Escalation Study of Hypofractionated Intensity-Modulated Radiation Therapy (Hypo-IMRT) Combining with Temozolomide (TMZ) Chemotherapy for Patients With Newly Diagnosed Glioblastoma Multiforme (GBM). November 2005-August 2010. Total Direct Costs: N/A.
11. Sub-Investigator (Investigator-initiated study). AstraZeneca (NCT00822887, COMIRB 06-0870). A Phase I Dose Escalation Study of Vandetanib (ZACTIMA, ZD6474) With Hypofractionated Stereotactic Radiotherapy in Patients with Recurrent Malignant Gliomas. PI: Changhu Chen; Co-investigators: Brain Kavanagh, Laurie Gaspar, Denise Damek, Kevin Lillehei, Steven Ojemann. March 2007-May 2010. Total Direct Costs: N/A, Study supported by AstraZeneca.
12. Principle Investigator. Roche 10-0037 (NCT00943826). A Randomized Double Blind, Placebo Controlled, Multicenter Phase III Trial of Bevacizumab, Temozolomide and Radiotherapy Followed by Bevacizumab and Temozolomide Versus Placebo, Temozolomide and Radiotherapy followed by Placebo and Temozolomide in Patients with Newly Diagnosed Glioblastoma. 1/11/2010-12/18/2015. Direct Cost \$129,700. Total Cost \$150,422.
13. Principle Investigator. AstraZeneca 11-1256. An Open Label, Multi-center, IRESSAT Clinical Access Program of Gefitinib 250 mg (IRESSAT) for the Continued Treatment of Patients in the United States who are Currently Benefiting or Have Benefited from Gefitinib Treatment. 9/21/2011-10/29/2015. Direct Costs \$2,270. Total Costs \$2,500.
14. Principle Investigator. Genentech 12-1297 (NCT01632228). A Randomized, Double-Blind, Placebo-Controlled, Multicenter Phase II Study Evaluating the Efficacy and Safety of Onartuzumab in Combination with Bevacizumab or Onartuzumab Monotherapy in Patients with

- Recurrent Glioblastoma GO27819. 11/1/2012-10/31/2015. Direct Costs \$186,634. Total Costs \$235,159.
15. Principle Investigator. COMIRB 10-0566. NCT0022665 A physician IND protocol for compassionate use, using Human Corticotropin Releasing Factor (H-CRF; Xerecept®) in a subject previously on Study 0501 who wishes to continue treatment. Closed 3/14/2014.
 16. Sub-Investigator. (Investigator-initiated study) NCT01209442, COMIRB 10-0264). A Pilot Phase II Trial of Hypofractionated Intensity-Modulated Radiation Therapy (Hypo-IMRT) Combining with Temozolomide (TMZ) and Bevacizumab for Patients with Newly Diagnosed Glioblastoma Multiforme (GBM). 9/16/2010-9/7/2014.
 17. Sub-Investigator. NCT00626990. COMIRB 10-0872. RTOG 0834 Phase III trial on Concurrent and Adjuvant Temozolomide chemotherapy in non- 1p/19q deleted anaplastic glioma. The CATNON Intergroup trial. Closed locally due to poor accrual.
 18. Principle Investigator. NCT010126493. COMIRB 11-0712. RTOG 0929 A randomized Phase I/II study of ABT-888 in combination with temozolomide in recurrent (temozolomide resistant) glioblastoma. Closed to accrual January 2013.
 19. Sub-Investigator. NCT01062399. RTOG 0913 Phase I/II trial of concurrent RAD001 (everolimus) with temozolomide/radiation followed by adjuvant RAD001/temozolomide in newly diagnosed glioblastoma. Closed to accrual.
 20. Principle Investigator. NCT01498328. COMIRB 13-1629. Celldex Therapeutics. A Phase II study of Rindopimut/GM-CSF in patients with relapsed EGFRVIII-positive glioblastoma. (The "ReACT" Study). 10/1/2012-9/30/2016. Direct Costs \$113,364. Total Costs \$128.624. Closed to accrual August 2013.
 21. Sub-Investigator. NCT00916409. COMIRB 13-0289. A prospective, multi-center trial of NovoTTF-100A together with temozolomide compared to temozolomide alone in patients with newly diagnosed GBM. Closed to accrual November 2014.
 22. Sub-Investigator. NCT01730950. COMIRB 13-3160. RTOG 1205. Randomized Phase II trial of concurrent bevacizumab and re-irradiation versus bevacizumab alone as treatment for recurrent glioblastoma. Closed to accrual December 2015.
 23. Sub-Investigator. Northwest BioTherapeutics. NCT00045968. COMIRB 11-1777. Protocol 020221 – A Phase II Clinical Trial Evaluation DCVax® - Brain, Autologous Dendritic Cells Pulsed with Tumor Lysate Antigen for the Treatment of Glioblastoma Multiforme. PI: Kevin Lillehei; Sub-investigators: Michael Graner, Denise Damek, Allen Waziri, Douglas Ney, Changhu Chen, Laurie Gaspar. Closed to accrual December 2016.
 24. Sub-investigator. NCT02073994. COMIRB 14-0012. Agios. Clinical Study Protocol AG120-C-002. A Phase 1, Multicenter, Open-Label, Dose-Escalation, Safety, Pharmacokinetic, Pharmacodynamic, and Clinical Activity Study of Orally Administered AG-120 in Subjects with Advanced Solid Tumors, Including Glioma, with and IDH1 Mutation. Closed to accrual.
 25. Principle Investigator. NCT02546102. COMIRB 15-1664. Immunocellular Therapeutics Ltd. ICT-107-301. A phase III randomized double-blind, controlled study of ICT-107 with maintenance temozolomide (TMZ) in newly diagnosed glioblastoma following resection and concomitant TMZ chemoradiotherapy. 4/1/2016-3/31/2019. Direct Costs: \$129,700. Total Costs: \$150,422.
 26. Principle Investigator. COMIRB 15-0714. AstraZeneca. Chart Review Study of Patients who Received IRESSA as Part of a Clinical Access Program (ICAP) in the United States. 11/30/2015-11/29/2020. Direct Costs: \$15,820. Total Costs: \$17,640. Closed to accrual October 2016.
 27. Principle Investigator. NCO02017717. COMIRB 14-0518. Bristol-Myers Squibb Research and Development Clinical Protocol CA209143. A Randomized Phase IIIB Open Label Study of Nivolumab versus Bevacizumab and a Safety Study of Nivolumab or Nivolumab in Combination with Ipilimumab in Adult Subjects with Recurrent Glioblastoma. 6/27/2014-6/26/2020. Direct Costs: \$102,218. Total Costs: \$116,662. Closed to accrual March 2015.
 28. Sub-Investigator. COMIRB 14-2216. NovoCure MSKCC Therapeutic/Diagnostic Protocol. Pilot study of NovoTTF-100A for Recurrent Atypical and Anaplastic Meningiomas.
 29. Sub-Investigator. COMIRB 14-1941. RTOG 1071/NCCTG N0577. Phase III Intergroup Study of Temozolomide Alone Versus Radiotherapy with Concomitant and Adjuvant Temozolomide Versus Radiotherapy with Adjuvant PCV Chemotherapy in Patients with 1p/19q Co-deleted Anaplastic Glioma. 1/1/2016-11/2018.

30. Sub-Investigator. NCT02573324. COMIRB 16-0200. RTOG 3508. A Randomized, Placebo Controlled Phase 2b/3 Study of ABT-414 with Concurrent Chemoradiation and Adjuvant Temozolomide in Subjects with Newly Diagnosed Glioblastoma (GBM) with Epidermal Growth Factor Receptor (EGFR) Amplification (Intelligence I). 1/1/2016-1/1/2018
31. Sub-Investigator. COMIRB 14-2216. NovoTTF-100A for Recurrent Atypical and Anaplastic Meningiomas.
32. Sub-Investigator. NCT02844439. COMIRB 16-0953. Kadmon Protocol KD019-208. A Phase 2, Multicenter Study of Tesevatinib Monotherapy in Patients with Recurrent Glioblastoma.
33. Principle Investigator. COMIRB 17-1610. AbbVie. A study of radiographically evident treatment effects in subjects with glioblastoma multiforme (GBM). 3/8/2018-3/7/2023. Direct Costs \$48,660. Total Costs \$61,312.
34. Sub-Investigator. NCT03150862. COMIRB 17-1486. BeiGene. Phase 1b/2 to assess safety, tolerability, and efficacy of BGB-290 in combination with radiation and/or temozolomide in first-line or recurrent/refractory glioblastoma.
35. Sub-Investigator. NCT02974621 . COMIRB 17-1986. UM1 LAO36/10067. A randomized phase 2 trial of cediranib and olaparib compared to bevacizumab in patients with recurrent glioblastoma who have not received prior VEGF therapy.
36. Co-Investigator. Meningioma Mommas. Determining the Therapeutic Potential of Targeting DNA Methylation in Meningiomas, and the Establishment of Aggressive and Recurrent Cell Lines 06/01/2018 to 05/31/2019. Total direct costs: \$29,443
37. Principle Investigator. COMIRB 15-1752. sIND UCH 20-0220. Ongoing Toca FC in patient previously enrolled on A Phase 2/3 Randomized, Open-Label Study of Toca 511, a Retroviral Replicating Vector, Combined with Toca FC versus Standard of Care in Subjects Undergoing Planned Resection for Recurrent Glioblastoma or Anaplastic Astrocytoma (Toca 5).

Bibliography:

Peer Reviewed Journal Publications:

1. **Damek DM**, Shuster EA. Pregnancy and multiple sclerosis. *Mayo Clin Proc.* 72(10):977-989, 1997.
2. **Damek DM**, Hochberg FH. Clinical aspects of brain tumor. *Curr Opin Neurol* 10:452-458, 1997.
3. McCarthy BJ, Davis FG, Freels S, Surawicz TS, **Damek DM**, Grutsch J, Menck HR, Laws ER, Jr. Factors associated with survival in patients with meningioma. *J Neurosurg.* 88:831-839, 1998.
4. **Damek DM**, Hochberg FH. The Pech, Peterson, Cairncross article reviewed. *Oncology.* 12(4):547-8, 1998.
5. Guha-Thakurta N, **Damek D**, Pollack C, Hochberg FH. Intravenous methotrexate as initial treatment for primary central nervous system lymphoma: response to therapy and quality of life of patients. *J Neurooncol.* 43(3):259-268, 1999.
6. **Damek DM**. Primary central nervous system lymphoma. *Curr Treat Options Neurol.* 5(3):213-222, 2003.
7. Baehring JM, **Damek D**, Martin EC, Betensky RA, Hochberg FH. Neurolymphomatosis. *Neuro Oncol.* 5(2):104-115, 2003.
8. Filley CM, Kleinschmidt-DeMasters BK, Lillehei KO, **Damek DM**, Harris JG. Gliomatosis cerebri: neurobehavioral and neuropathological observations. *Cogn Behav Neurol.* 16(3):149-159, 2003.
9. **Damek DM**. Paraneoplastic retinopathy/optic neuropathy. *Curr Treat Options Neurol.* 7(1):57-67, 2005.
10. Lillehei KO, Simon J, Gaspar L, **Damek DM**. Non-small-cell lung cancer with brain metastasis. *Oncology (Williston Park).* 18(14):1725-1728, 2004.
11. Yu X, Owens GP, Ritchie AM, Burgoon MP, **Damek DM**, Keays KM, Gilden DH. Single-cell RT-PCR analysis of cerebrospinal fluid B cell clonality and immunoglobulin heavy and light chain variable region gene mutation in diffuse large B-cell lymphoma. *Gene Ther Mol Biol.* 9:1-6, 2005.
12. Rollins KE, Kleinschmidt-DeMasters BK, Corboy JR, **Damek DM**, Filley CM. Lymphomatosis cerebri as a cause of white matter dementia. *Hum Pathol.* 36(3):282-290, 2005.

13. Schwer AL, **Damek DM**, Kavanagh BD, Gaspar LE, Lillehei K, Stuhr K, Chen C. A phase I dose-escalation study of fractionated stereotactic radiosurgery in combination with gefitinib in patients with recurrent malignant gliomas. *Int J Radiat Oncol Biol Phys.* 70(4):993-1001, 2008.
14. Kleinschmidt-DeMasters BK, **Damek DM**, Lillehei KO, Dogan A, Giannini C. Epstein Barr virus-associated primary CNS lymphomas in elderly patients on immunosuppressive medications. *J Neuropathol Exp Neurol.* 67(11):1103-1111, 2008.
15. **Damek DM**, Lillehei KO, Kleinschmidt-DeMasters BK. Aspergillus terreus brain abscess mimicking tumor progression in a patient with treated glioblastoma multiforme. *Clin Neuropathol.* 27(6):400-407, 2008.
16. **Damek DM**. Cerebral edema, altered mental status, seizures, acute stroke, leptomeningeal metastases, and paraneoplastic syndrome. *Emerg Med Clin North Am.* 27(2):209-229, 2009.
17. Kleinschmidt-DeMasters BK, **Damek DM**. The imaging and neuropathological effects of Bevacizumab (Avastin) in patients with leptomeningeal carcinomatosis. *J Neurooncol.* 96:375-384, 2010.
18. **Damek DM**. Cerebral edema, altered mental status, seizures, acute stroke, leptomeningeal metastases, and paraneoplastic syndrome. *Hematol Oncol Clin North Am.* 24(3):515-535, 2010.
19. Chen C, **Damek D**, Gaspar LE, Waziri A, Lillehei K, Kleinschmidt-DeMasters BK, Robischon M, Stuhr K, Rusthoven KE, Kavanagh BD. Phase I trial of hypofractionated intensity-modulated radiotherapy with temozolomide chemotherapy for patients with newly diagnosed glioblastoma multiforme. *Int J Radiat Oncol Biol Phys.* 81(4):1066-1074, 2011.
20. Rusthoven KE, Olsen C, Franklin W, Kleinschmidt-DeMasters BK, Kavanagh BD, Gaspar LE, Lillehei K, Waziri A, **Damek DM**, Chen C. Favorable prognosis in patients with high-grade glioma with radiation necrosis: The University of Colorado reoperation series. *Int J Radiat Oncol Biol Phys.* 81(1):211-217, 2011.
21. Fields EC, **Damek D**, Gaspar LE, Liu AK, Kavanagh BD, Waziri A, Lillehei K, Chen C. Phase I dose escalation trial of vandetanib with fractionated radiosurgery in patients with recurrent malignant gliomas. *Int J Radiat Oncol Biol Phys.* 82(1):51-57, 2012.
22. Nielsen AS, **Damek DM**. Window of opportunity: flexion myelopathy after drug overdose. *J Emerg Med.* 42(1):36-39, 2012.
23. Khalil A, Serracino H, **Damek DM**, Ney D, Lillehei KO, Kleinschmidt-DeMasters BK. Genetic characterization of gliomas arising in patients with multiple sclerosis. *J Neurooncol.* 109(2):261-272, 2012.
24. Reddy K, **Damek D**, Gaspar LE, Ney D, Waziri A, Lillehei K, Stuhr K, Kavanaugh BD, Chen C. Phase II trial of hypofractionated IMRT with Temozolomide for patients with newly diagnosed glioblastoma multiforme. *Int J Radiat Oncol Biol Phys.* 84(3):655-660, 2012.
25. Schmidt Y, Kleinschmidt-DeMasters BK, Aisner DL, Lillehei KO, **Damek D**. Anaplastic PXA in adults: case series with clinicopathologic and molecular features. *J Neurooncol.* 111(1):59-69, 2013.
26. Reddy K, Gaspar, LE, Kavanagh BD, Waziri A, **Damek DM**, Ney D, Lillehei KO, Chen C. Prospective evaluation of health-related quality of life in patients with glioblastoma multiforme treated on a phase II trial of hypofractionated IMRT with temozolomide. *J Neurooncol.* 114:111-116, 2013.
27. **Damek DM**. Leptomeningeal enhancement in a 58-year-old woman. *Oncology (Williston Park).* 28:438-440, 2014.
28. Poonia S, Berge EM, Aisner DL, **Damek D**, Doebele RC. EGFR exon 19 deletion mutations and systemic/central nervous system miliary metastasis: Clinical correlations and response to therapy. *Clin Lung Cancer.* 15(5):387-389, 2014.
29. Rusthoven CG, Carlson JA, Waxweiler TV, Dally MJ, Baron AE, Yeh N, Gaspar LE, Liu AK, Ney DE, **Damek DM**, Lillehei KO, Kavanagh BD. The impact of adjuvant radiation therapy for high-grade gliomas by histology in the United States population. *Int J Radiat Oncol Biol Phys.* 90(4):894-902, 2014.
30. Ney D, Kleinschmidt-DeMasters BK, Carlson J, **Damek D**, Gaspar L, Kavanagh B, Waziri A, Lillehei K, Reddy K, Chen C. Extent of cerebral radionecrosis in patients with newly diagnosed glioblastoma (GBM) treated on a clinical trial with Hypofractionated intensity-modulated radiation

- therapy (Hypo-IMRT) combined with Temozolomide (TMZ) and Bevacizumab (BEV). *Neuro Oncol.* 16(Supple 5); v192, 2014.
31. Ney DE, Carlson JA, **Damek DM**, Gaspar LE, Kavanagh BD, Kleinschmidt-DeMasters BK, Waziri AE, Lillehei KO, Reddy K, Chen C. Phase II trial of hypofractionated intensity-modulated radiation therapy combined with temozolomide and bevacizumab for patients with newly diagnosed glioblastoma. *J Neurooncol.* 122:135-143, 2015.
 32. Carlson JA, Reddy K, Gaspar LE, Ney D, Kavanagh BD, **Damek D**, Lillehei K, Chen C. Hypofractionated-intensity modulated radiotherapy (hypo-IMRT) and temozolomide (TMZ) with or without bevacizumab (BEV) for newly diagnosed glioblastoma multiforme (GBM): a comparison of two prospective phase II trials. *J Neurooncol.* 123:251-257, 2015.
 33. Mohler A, Ney D, Gaspar L, **Damek D**, Kavanagh B, Reddy K, Chen C. QOL-16 Health-related quality of life (HRQoL) in a phase II trial of hypofractionated intensity-modulated radiation therapy (hypo-IMRT) with temozolomide (TMZ) and bevacizumab (BEV) for patients with newly diagnosed glioblastoma multiforme (GBM). *Neuro Oncol.* 17:v188-v194, 2015.
 34. Amini A, Atloos B, Karam SD, Waxwelier TV, Rusthoven CG, Gaspar LE, Honce JM, **Damek DM**, Ney DE, Ormond DR, Lillehei KO, Chen C, Kavanagh BD, Liu AK. Outcomes of symptomatic compared to asymptomatic recurrences in patients with glioblastoma multiforme (GBM). *J Radiat Oncol.* 5(1):33-39, 2016.
 35. Trusheim J, Dunbar E, Battiste J, Iwamoto F, Mohile N, **Damek D**, Bota DA, Connelly J. A state-of-the-art review and guidelines for tumor treating fields treatment planning and patient follow-up in glioblastoma. *CNS Oncol.* 6(1):29-43, 2017. doi: 10.2217/cns-2016-0032.
 36. Oushy S, Sillau SH, Ney DE, **Damek DM**, Youssef AS, Lillehei KO, Ormond DR. New-onset seizure during and after brain tumor excision: A risk assessment analysis. *J Neurosurg.* 128(6):1713-1718, 2018.
 37. Ung TH, Ney DE, **Damek D**, Rusthoven CG, Youssef AS, Lillehei KO, Ormond DR. The Neurologic Assessment in Neuro-Oncology (NANO) Scale as an Assessment Tool for Survival in Patients with Primary Glioblastoma. *Neurosurg.* 84(3):687-695, 2019
 38. Cloughesy TF, Petrecca K, Walbert T, Butowski N, Salacz M, Perry J, **Damek D**, Bota D, Bettegowda C, Zhu J-J, Iwamoto F, Placantonakis D, Kim L, Elder B, Kaptain G, Cachia D, Moshel Y, Brem S, Piccioni D, Landolfi J, Chen CC, Gruber H, Rao AR, Hogan D, Accomando W, Ostertag D, Montellano TT, Kheoh T, Kabbinavar F, Vogelbaum MA. Effect of Vocimagene Amiretorepvec in combination with Flucytosine vs standard of care on survival following tumor resection in patients with recurrent high-grade glioma. *JAMA Oncol.* 6(12):1939-1946, 2020. doi:10.1001/jamaoncol.2020.3161
 39. Tatman PD, Wroblewski TH, Fringuello AR, Scherer SR, Foreman WB, **Damek DM**, Lillehei K, Youssef AS, Jensen RL, Graner MW, Ormond DR. High-throughput mechanistic screening of epigenetic compounds for the potential treatment of meningiomas. *J Clin Med.* 10(14):3150, 2021. doi: 10.3390/jcm10143150. PMID: 34300316; PMCID: PMC8303324.
 40. Tatman PD, Wroblewski TH, Fringuello AR, Scherer SR, Foreman WB, **Damek DD**, Youssef AS, Lillehei KO, Jensen RL, Graner MW, Ormond DR. High-throughput screening of epigenetic inhibitors in meningiomas identifies HDAC, G9a, and Jumonji-domain inhibition as potential therapies. *J Neurol Surg B Skull Base.* Accepted 6/20/2022. doi: 10.1055/a-1885-1257
 41. Belanger K, Ung TH, **Damek D**, Lillehei KO, Ormond DR. Concomitant Temozolomide plus radiotherapy for high-grade and recurrent meningioma: a retrospective chart review. *BMC Cancer.* 22(1):367, 2022. doi:10.1186/s12885-022-09340-7
 42. Tatman PD, Wroblewski TH, Fringuello AR, Scherer SR, Foreman WB, **Damek DM**, Lillehei KO, Jensen RL, Youssef AS, Ormond DR, Graner MW. Targeting DNA Methyl Transferases with Decitabine in Cultured Meningiomas. *World Neurosurg.* 2022;162:e99-e119. doi:10.1016/j.wneu.2022.02.108
 43. Brastianos PK, Twohy EL, Cerstner ER, Kaufmann TJ, Iafrate AJ, Lennerz J, Jeyapalan S, Piccioni DE, Monga V, Fadul CE, Schiff D, Taylor JW, Chowdhary SA, Bettegowda C, Anstas G, De La Fuente M, Anderson MD, Shonka N, Damek D, Carrillo J, Kunschner-Ronan LJ, Chaudhary R, Jaeckle KA, Senecal FM, Kaley T, Morrison T, Thomas AA, Welch MR, Iwamoto F, Cachia D, Cohen AL, Vora S, Knopp M, Dunn IF, Kumthekar P, Sarkaria J, Geyer S, Carrero XW, Martinez-Lage M, Cahill DP, Brown PD, Giannini C, Santagata S, Barker FG 2nd, Galanis E. Alliance

A071401: Phase II Trial of Focal Adhesion Kinase Inhibition in Meningiomas With Somatic NF2 Mutations. *J Clin Oncol.* 2022 Oct 26; JCO2102371. [Epub ahead of print] PubMed PMID 36288512

Chapters:

1. **Damek DM.** Melanoma. *In:* Cancer Neurology in Clinical Practice (Wen P, Schiff D, eds), Humana Press, Inc. Totowa, NJ, 339-354, 2003.
2. **Damek DM.** Neuro-Oncology. *In:* Educational Review Manual in Neurology (Holmes G, Cohen J eds), Castle Connolly Graduate Medical School Publishing, Ltd., New York, NY, 459-492, 2006.
3. Cook SK, **Damek DM.** Brain Tumors. *In:* Oncology Nursing Secrets (Gates RA, Fink RM eds), Mosby Elsevier, St. Louis, MO, 221-234, 2008.
4. **Damek DM.** Neuro-Oncology. *In:* Educational Review Manual in Neurology 2nd Edition (Levin M, Holmes G, Cohen J eds). Castle Connolly Graduate Medical School Publishing, Ltd., New York, NY, 545-579, 2008.
5. **Damek DM.** Neurological Complications of Melanoma. *In:* Cancer Neurology in Clinical Practice 2nd Edition (Wen P, Schiff D eds), Humana Press, Inc. Totowa, NJ, 523-553, 2008.
6. **Damek DM.** Neurologic Complications of Chemotherapy. *In:* Medical Care of Cancer Patients (Yeung J, Escalante C, Gagel R eds), BC Decker Inc. People's Medical Publishing House. Shelton, CT, 387-401, 2009.

Competitive Scientific Abstracts:

1. **Damek DM,** Henson J. Spinal Cord Astrocytoma, Response to PCV chemotherapy, Poster presentation at the Society of Neuro-Oncology Meeting, Charlottesville, VA. October 1997.
2. **Damek DM,** Brain Abscess in Cancer Patients, Platform presentation at the American Academy of Neurology Meeting, Minneapolis, MN. April 1998.
3. **Damek DM,** Hochberg FH. Neurolymphomatosis. Poster presentation at Society of Neuro-Oncology Annual Meeting, Scottsdale, AZ. November 1999.
4. Chen C, **Damek D,** Gaspar LE, K. Lillehei, OjemannvS, Raben D, and Kavanagh B. A Phase I Dose Escalation Study of Hypofractionated Stereotactic Radiotherapy in Combination with ZD1839 (IRESSA®) in Patients with Recurrent Malignant Gliomas. Poster discussion at 2006 ASTRO Annual Meeting, Philadelphia, PA. November 5-9, 2006.
5. Schwer A, McCammon R, Kavanagh B, Gaspar L, **Damek D,** Chen C. Magnetic resonance imaging (MRI) T1 and T2 volumetric changes and their implications after hypofractionated stereotactic radiotherapy (SRS) in patients with recurrent malignant gliomas. American Society for Radiation Oncology (ASTRO) 49st Annual Meeting. November 1, 2007. *International Journal of Radiation Oncology Biology Physics* Vol. 69, Issue 3, Supplement, Page S167.
6. Swinnen LJ, Rankin C, Rushing EJ, Hutchins LF, **Damek DM,** Barger GR. Southwest Oncology Group S9811: A phase II study of hydroxyurea for unresectable meningioma. American Society of Clinical Oncology 45th Annual Meeting, Orlando, FL. May 29-June 2, 2009.
7. Chen C, **Damek D,** Waziri A, Gaspar L, Lillehei K, Kane M, Robischon M, Kavanagh B. A phase I dose per fraction escalation study of hypofractionated intensity-modulated radiation therapy with temozolomide chemotherapy for patients with newly diagnosed glioblastoma. American Society of Clinical Oncology 45th Annual Meeting, Orlando, FL. May 29-June 2, 2009. *International Journal of Radiation Oncology Biology Physics* Vol. 75, Issue 3, Supplement, Page S103.
8. Allen AB, **Damek DM.** Alternating weekly temozolomide as salvage therapy in malignant gliomas. Abstract No. 254. 2009 Joint Meeting of the Society for Neuro-Oncology and the AANS/CNS Section on Tumors, New Orleans, LA. October 22-24, 2009. *Neuro-oncology* 2009; 11(5): 622.
9. **Damek DM,** Lillehei KO, Kleinschmidt-DeMasters BK. Prognosis and response to treatment of pleomorphic xanthoastrocytoma with anaplastic features. Abstract No. 288. 2009 Joint Meeting of the Society for Neuro-Oncology and the AANS/CNS Section on Tumors, New Orleans, LA. October 22-24, 2009.
10. **Damek DM,** Kleinschmidt-DeMasters BK. The imaging and neuropathological effects of bevacizumab (Avastin) in patients with leptomeningeal carcinomatosis. Abstract No. 346. 2009 Joint Meeting of the Society for Neuro-Oncology and the AANS/CNS Section on Tumors, New Orleans, LA. October 22-24, 2009.

11. Chen C, **Damek DM**, Waziri AE, Gaspar LE, Lilliehei KO, Kane M, Robischon BK. A Phase I trial of dose per fraction escalation of hypofractionated IMRT with Temozolomide chemotherapy for patients with newly diagnosed glioblastoma multiforme Abstract No. 426. 2009 Joint Meeting of the Society for Neuro-Oncology and the AANS/CNS Section on Tumors, New Orleans, LA. October 22-24, 2009.
12. Swinnen LJ, Rankin C, Rushing EJ, Laura HF, **Damek DM**, Barger GR. Phase II study of hydroxyurea for unresectable meningioma (Southwest Oncology Group S9811). Abstract No. 2063. American Society of Clinical Oncology (ASCO) 45th Annual Meeting. Orlando, FL. May 29 – June 2, 2009.
13. Chen C, **Damek DM**, Waziri A, Gaspar LE, Lillehei KO, Kane M, Robischon M, Kavanagh BD. A Phase I Dose Per Fraction Escalation Study of Hypofractionated Intensity-Modulated Radiation Therapy with Temozolomide Chemotherapy for Patients with Newly Diagnosed Glioblastoma. Oral Presentation. American Society for Radiation Oncology (ASTRO) 51st Annual Meeting. Chicago, IL. November 1-5, 2009.
14. Fields E, **Damek DM**, Liu A, Gaspar LE, Kavanagh BD, Waziri A, Lillehei KO, Chen C. Phase I Dose Escalation Trial of Vandetanib with Fractionated Radiosurgery in Patients with Recurrent Malignant Gliomas. American Society for Radiation Oncology (ASTRO) 52nd Annual Meeting. San Diego, CA. October 31-November 4, 2010.
15. Rusthoven KE, Olsen C, Franklin W, Kleinschmidt-DeMasters B.K., Kavanagh B, Gaspar LE, Lillehei KO, Waziri A, **Damek DM**, Chen C. Favorable Prognosis in Patients with High-Grade Glioma with Radiation Necrosis: The University of Colorado Denver Re-operation Series. American Society for Radiation Oncology (ASTRO) 52nd Annual Meeting. San Diego, CA. October 31-November 4, 2010.
16. Chen CH, **Damek D**, Lui A, Gaspar LE, Waziri A, Lillehei K, Kavanagh B. Phase I dose escalation trial of vandetanib with fractionated radiosurgery I patients with recurrent malignant gliomas. The 15th Annual Scientific Meeting of the Society for Neuro-Oncology (SNO). New Orleans, LA. November 18-21, 2010.
17. Swinnen LJ, Rankin C, Rushing EJ, Hutchins LF, **Damek DM**, Barger GR. Objective response rate of unresectable benign meningioma to hydroxyurea: Southwest Oncology Group Phase II Trial S9811. The 15th Annual Scientific Meeting of the Society for Neuro-Oncology (SNO). New Orleans, LA, November 18-21, 2010. *Neuro-Oncology*. 12(suppl_4):iv69–iv78, NOVEMBER 2010
18. Chen CH, Olsen C, Franklin W, Kleinschmidt-DeMasters BK, Kavanagh BD, Lillehei K, Waziri A, **Damek D**, Gaspar LE. Implication of radiation necrosis in patient with high-grade glioma. The 15th Annual Scientific Meeting of the Society for Neuro-Oncology (SNO). New Orleans, LA. November 18-21, 2010. *Neuro-Oncology*. 12(suppl_4):iv105–iv112, NOVEMBER 2010
19. Chen CH, **Damek D**, Gaspar LE, Waziri A, Lillehei K, Kleinschmidt-DeMasters BK, Robischon M, Stuhr K, Rusthoven KE, Kavanagh BD. Phase 1 trial of hypofractionated intensity-modulated radiotherapy with temozolomide chemotherapy for patients with newly diagnosed glioblastoma multiforme. American Society for Radiation Oncology (ASTRO) 53rd Annual Meeting, Miami Beach, FL. October 2-6, 2011.
20. Reddy K, **Damek DM**, Gaspar L, Ney D, Kavanagh B, Waziri A, Lillehei K, Stuhr K, Chen C. Phase II Trial of Hypofractionated Intensity Modulated Radiotherapy to 60 Gy in 10 Fractions with Temozolomide Chemotherapy for Patients with Newly Diagnosed Glioblastoma Multiforme. American Society for Radiation Oncology (ASTRO) 53rd Annual Meeting, Miami Beach, FL. October 2-6, 2011.
21. Chen CH, **Damek D**, Gaspar LE, Ney D, Waziri A, Lillehei K, Kavanagh BD. Phase II trial of hypofractionated intensity-modulated radiotherapy with concurrent and adjuvant temozolomide for patients with newly diagnosed glioblastoma multiforme. The 16th Annual Scientific Meeting of the Society for Neuro-Oncology (SNO), Anaheim, CA. November 17-20, 2011. *Neuro-Oncology*. 13(suppl_3):iii127–iii133, NOVEMBER 2011
22. Serracino H, Khalil A, **Damek DM**, Ney DE, Lillehei KO, Kleinschmidt-DeMasters BK. Gliomas arising in patients with multiple sclerosis have no distinctive genetic features. Presented in poster format at the 101st annual United States and Canadian Pathology meeting (USCAP), Vancouver, BC. March 17-23, 2012.
23. Schmidt Y, Kleinschmidt-DeMasters BK, Aisner D, Lillehei KO, **Damek D**. *BRAF V600E* mutation is seen in 50% of adult pleomorphic xanthoastrocytoma with anaplastic features but does not predict prognosis for individual patients. Presented in poster format at the 101st annual United States and Canadian Pathology meeting (USCAP), Vancouver, BC. March 17-23, 2012.
24. Reddy K, **Damek D**, Gaspar LE, Ney D, Kavanagh BD, Waziri A, Lillehei K, Stuhr K, Chen C. Hypofractionated intensity modulated radiation therapy altered patterns of failure in patients with

- glioblastoma multiforme treated on a Phase II trial. American Society for Radiation Oncology (ASTRO) 54th Annual Meeting, Boston, MA. November 1, 2012. *International Journal of Radiation Oncology Biology Physics* Vol. 84, Issue 3, Supplement, Page S268.
25. Clark S, Carlson JA, Gaspar LE, Ney DE, Chen C, Kavanagh B, **Damek DM**. Meningioma WHO Grade II-III: Temozolomide with and without radiation in the management of WHO Grade II and III meningiomas. The 17th Annual Scientific Meeting of the Society for Neuro-Oncology (SNO), Washington, DC. November 15-18, 2012. *Neuro-Oncology*. 14(suppl_6):vi56–vi60, OCTOBER 2012
 26. **Damek DM**, Ney DE, Borges MT, Colantoni W, Bert R. Arterial spin labeling perfusion and dynamic susceptibility contrast perfusion MRI in posttreatment malignant glioma evaluation. The 17th Annual Scientific Meeting of the Society for Neuro-Oncology (SNO), Washington, DC. November 15-18, 2012. *Neuro-Oncology*. 14(suppl_6):vi120–vi128, OCTOBER 2012
 27. Reddy K, **Damek D**, Gaspar L, Ney D, Kavanagh B, Waziri A, Lillehei K, Stuhr K, Chen C. Patterns of Failure in Patients with Glioblastoma Treated with Hypofractionated Intensity-Modulated Radiotherapy and Temozolomide on a Phase II Trial. The 17th Annual Scientific Meeting of the Society for Neuro-Oncology (SNO), Washington, DC. November 15-18, 2012. *Neuro-Oncology*. 14(suppl_6):vi133–vi141, OCTOBER 2012
 28. Lauro C, Ney D, Bert R, Waziri A, Kleinschmidt-DeMasters BK, **Damek D**, Gaspar L. The AANS/CNS section of Tumors: Tenth Annual Biennial Satellite Tumor Symposium, New Orleans, LA. April 26-27, 2013.
 29. Ney D, Carlson JA, **Damek DM**, Blatchford PJ, Gaspar LE, Kavanagh BD, Waziri A, Lillehei KO, Reddy K, and Chen C. A pilot phase II trial of hypofractionated intensity-modulated radiation therapy (hypo-IMRT) combined with Temozolomide (TMZ) and Bevacizumab (BEV) for patients with newly diagnosed glioblastoma multiforme (GBM). The 4th Quadrennial Meeting of the World Federation of Neuro-Oncology in conjunction with the 18th Annual Meeting of the Society for Neuro-Oncology (SNO), San Francisco, CA. November 21-24, 2013.
 30. Mrachek K, Lummus S, **Damek DM**, Kleinschmidt-DeMasters. Erdheim-Chester disease mimicking CLIPPERS. CAP '14 (College of American Pathologists), Chicago, IL. September 7-10, 2014.
 31. Carlson JA, Reddy K, Gaspar LE, Ney D, Kavanagh BD, **Damek D**, Lillehei K, Chen C. Hypofractionated-intensity modulated radiotherapy (hypo-IMRT) and temozolomide (TMZ) with and without bevacizumab (BEV) for glioblastoma multiforme (GBM): a comparison of two prospective phase II trials. ASTRO 56th Annual Meeting, San Francisco, CA. September 14-17, 2014.
 32. Carlson JA, Ney D, Reddy K, Gaspar LE, Kavanagh BD, **Damek D**, Lillehei K, Chen C. A phase II trial of hypofractionated intensity-modulated radiation therapy (hypo-IMRT) combined with temozolomide (TMZ) and bevacizumab (BEV) for patients with newly diagnosed glioblastoma multiforme (GBM). ASTRO 56th Annual Meeting, San Francisco, CA. September 14-17, 2014.
 33. Leppert M, **Damek D**, Palmer L, Ney D. Depression Screening in Patients with Primary Brain Tumors. The Neurohospitalist Society Second Annual Meeting, Denver, CO. September 26-27, 2014.
 34. Ney DE, Carlson JA, **Damek DM**, Gaspar LE, Kavanagh BD, Kleinschmidt-DeMasters BK, Waziri AE, Lillehei KO, Reddy K, Chen C. Phase II trial of hypofractionated intensity-modulated radiation therapy combined with temozolomide and bevacizumab for patients with newly diagnosed glioblastoma. 19th Annual Meeting of the Society for Neuro-Oncology (SNO), Miami, FL. November 13-16, 2014.
 35. Ney DE, Kleinschmidt-DeMasters BK, Carlson JE, **Damek DM**, Gaspar LE, Kavanagh BD, Waziri A, Lillehei KO, Chen C. Extent of cerebral necrosis in patients with newly diagnosed glioblastoma (GBM) treated on a clinical trial with hypofractionated intensity-modulated radiation therapy (hypo-IMRT) combined with temozolomide (TMZ) and bevacizumab (BEV). The 19th Annual Meeting of the Society for Neuro-Oncology (SNO), Miami, FL. November 13-16, 2014. *Neuro-Oncology*, Volume 16, Issue suppl_5, November 2014, Page v192, <https://doi.org/10.1093/neuonc/nou270.21>.
 36. Altoos B, Amini A, Karam S, Gaspar L, Honce J, **Damek D**, Ney D, Ormond R, Lillehei K, Kavanagh B, Liu A. Evaluation of Symptomatic Versus Asymptomatic Recurrences in Patients with Glioblastoma Multiforme (GBM). The 57th ASTRO Annual Meeting. San Antonio, TX. October 18-21, 2015.
 37. Mohler A, Ney D, Gaspar L, **Damek D**, Kavanagh B, Reddy K, Chen C. Health-Related Quality of Life (HRQoL) in a Phase II Trial of Hypofractionated Intensity-Modulated Radiation Therapy (hypo-IMRT) Combined with Temozolomide (TMZ) and Bevacizumab (BEV) for Patients with Newly Diagnosed

- Glioblastoma Multiforme (GBM). 20th Annual Society of Neuro-Oncology Annual Scientific Meeting and Education Day. San Antonio, TX. November 19-22, 2015.
38. Battiste JD, Sughrue M, Pan E, Sewell J, Fink K, Jeyapalan S, **Damek D**, Bota D, Pittman N, Villano J. Patterns of Recurrence in Low Field Intensity Regions During TTFIELDS Treatment. Poster presentation at Society of Neuro-Oncology 21st Annual Meeting and Education Day. Scottsdale, AZ. November 17-20, 2016.
 39. Trusheim J, Dunbar E, Battiste J, Iwamoto F, Mohile N, **Damek D**, Bota DA, Connelly J. Development of Practice Algorithms to Guide Treatment Planning With TTFIELDS for the Management of Glioblastoma. Poster presentation at Society of Neuro-Oncology 21st Annual Meeting and Education Day. Scottsdale, AZ. November 17-20, 2016.
 40. Mohler, A, Kleinschmidt-DeMasters BK, **Damek D**. Recurrent episodes of stroke-like migraine attacks after radiation therapy (SMART) syndrome in adults. Abstract. Society of Neuro-Oncology 21st Annual Meeting and Education Day. Scottsdale, AZ. November 17-20, 2016. *Neuro-oncology* 2016 (18): 143.
 41. Ung TH, Ney D, **Damek D**, Youssef AS, Lillehei KO, Ormond R. Using the Neurologic Assessment in Neuro-Oncology (NANO) Scale as a Predictive Assessment Tool for Survival in Patients with Primary Glioblastoma. Abstract. Society of Neuro-Oncology 21st Annual Meeting and Education Day. Scottsdale, AZ. November 17-20, 2016.
 42. Ormond DR, **Damek DM**, Willard N, Ewalt MD, Kleinschmidt-DeMasters BK. Fusion testing in adult versus pediatric low and high grade brain tumors for eligibility for trials. Abstract. Society of Neuro-Oncology 23rd Annual Meeting. New Orleans, LA. November 20-24, 2018.
 43. Tatman PD, Fringuello A, **Damek DM**, Youssef S, Jensen R, Lillehei KO, Graner M. High-throughput drug screening of FDA approved cancer drugs reveals novel therapies for patients with chordomas. Abstract. North American Skull Base Society Annual Meeting. Orlando, FL. February 15-17, 2019. *J Neurol Surg B Skull Base* 2019; 80(S 01): S1-S244 DOI: 10.1055/s-0039-1679578
 44. Tatman PD, Fringuello A, Jensen R, **Damek DM**, Lillehei KO, Graner M. Profiling meningioma sensitivity to epigenetic inhibition using a high-throughput pharmacological screen in meningioma cell lines. Abstract. North American Skull Base Society Annual Meeting. Orlando, FL. February 15-17, 2019. *J Neurol Surg B Skull Base* 2019; 80(S 01): S1-S244 DOI: 10.1055/s-0039-1679513
 45. Tatman PD, Fringuello A, Jensen R, **Damek DM**, Lillehei KO, Graner M. Screening of FDA approved compounds for cancer therapy in meningioma cell lines identifies novel treatments for meningiomas. Abstract. North American Skull Base Society Annual Meeting. Orlando, FL. February 15-17, 2019. *J Neurol Surg B Skull Base* 2019; 80(S 01): S1-S244. DOI: 10.1055/s-0039-1679451
 46. Tatman PD, Fringuello A, Wroblewski T, Scherer S, Foreman W, Ormond DR, **Damek DM**, Lillehei KO, Jensen R, Graner M. High-throughput drug screening of meningiomas identifies HDAC inhibitors as promising targets across grades. Abstract. Society of Neuro-Oncology Annual Scientific Meeting. Phoenix, AZ. November 22-24, 2019. *Neuro Oncol.* 2019 Nov; 21(Suppl 6): vi68–vi69. Published online 2019 Nov 11. doi: 10.1093/neuonc/noz175.277
 47. Cloughesy T, Petrecca K, Walbert T, Butowski N, Salacz M, Perry J, **Damek, D** et al. TOCA 5: Toca 511 & Toca FC Versus Standard of Care in Patients With Recurrent High Grade Glioma (rHGG). Platform Presentation. Society of Neuro-Oncology Annual Scientific Meeting. Phoenix, AZ. November 22-24, 2019. *Neuro Oncol.* 2019 Nov; 21(Suppl 6): vi284. Published online 2019 Nov 22. doi: 10.1093/neuonc/noz219.1199
 48. Foreman W, Tatman PD, Fringuello A, Wroblewski T, Scherer S, **Damek D**, Lillehei K, Jensen R, Ormond D, Graner M. High-throughput screening of epigenetic inhibitors in chordoma and chondrosarcoma. Abstract. North American Skull Base Society Annual Meeting. San Antonio, TX. February 7-9, 2020. *J Neurol Surg B Skull Base* 2020; 81(S 01): S1-S272 DOI: 10.1055/s-0040-1702418
 49. Wroblewski T, Tatman PD, Fringuello A, Foreman W, Scherer S, **Damek D**, Lillehei K, Jensen R, Ormond D, Graner M. Inhibition of PDGFR may be a viable treatment option for meningioma. Abstract. North American Skull Base Society Annual Meeting. San Antonio, TX. February 7-9, 2020. *J Neurol Surg B Skull Base* 2020; 81(S 01): S1-S272. DOI: 10.1055/s-0040-1702356
 50. Tatman PD, Fringuello A, Wroblewski T, Foreman W, Scherer S, **Damek D**, Lillehei K, Jensen R, Ormond D, Graner M. Romidepsin is a possible treatment for meningiomas through dual inhibition of class 1 and 2 HDA. Abstract. North American Skull Base Society Annual Meeting. San Antonio, TX. February 7-9, 2020. *J Neurol Surg B Skull Base* 2020; 81(S 01): S1-S272. DOI: 10.1055/s-0040-1702390

51. Wen PY, de Groot J, Battiste JD, Goldlust SA, **Damek D**, Garner JS, Simpson J, Olivero A, Cloughesy T. Interim results of a Phase 2 study to evaluate the PI3K/mTOR inhibitor paxalisib (GDC-0084) given to newly diagnosed glioblastoma patients with unmethylated O⁶-methylguanine-methyltransferase promoter. Poster presentation at Society of Neuro-Oncology (SNO) 25th Annual Meeting (Virtual). November 19-21, 2020.
52. Belanger K, Ung TH, Ney D, Lillehei KO, Rusthoven C, **Damek DM**, Ormond DR. Concomitant Temozolomide Plus Radiotherapy Demonstrates Favorable Progression Free Survival in Recurrent Meningioma. Accepted Abstract 2020 Congress of Neurological Surgeons (CNS) Annual Meeting, Miami Beach, FL. September 12-16, 2020. *Clinical Neurosurgery* 2020; 67(1): 297.
53. Wen PY, de Groot J, Battiste JD, Goldlust SA, **Damek D**, Garner JS, Simpson J, Olivero A, Cloughesy T. Pharmacokinetics of paxalisib in a phase 2 clinical study in glioblastoma (GBM) with unmethylated O⁶-methylguanine-methyltransferase (MGMT) promoter status. Poster presentation at the American Association of Cancer Research (AACR) – Virtual Annual Meeting. Virtual, April 10-15, 2021 and May 17-21, 2021.
54. Walbert T, **Damek D**, Martinez-Nina L, Piccioni D, Singer S, Cloughesy T. Extended benefits in patients with recurrent high grade glioma that continuously receive Toca FC after Toca 511 Treatment. Platform presentation at the Society of Neuro-oncology Annual Meeting, November 19-21, 2021. *Neuro-Oncology*, Volume 23, Issue Supplement_6, November 2021, Pages vi58–vi59.
55. Tatman P, Wroblewski T, Fringuello A, Scherer S, Foreman W, **Damek D**, Youssef S, Lillehei K, Ormond D, Graner M. Screening of FDA-approved compounds for the treatment of chordoma, with in vivo validation using three different xenograft models, identifies brigatinib as a potential treatment. Platform presentation at the Society of Neuro-oncology Annual Meeting, November 19-21, 2021. *Neuro-Oncology*, Volume 23, Issue Supplement_6, November 2021, Pages vi83–vi84.
56. Wroblewski T, Tatman P, Fringuello A, Scherer S, Foreman W, **Damek D**, Youssef S, Lillehei K, Ormond D, Graner M. High-throughput screening of FDA-approved compounds in glioma and glioblastoma identifies novel therapeutics. Platform presentation at the Society of Neuro-oncology Annual Meeting, November 19-21, 2021. *Neuro-Oncology*, Volume 23, Issue Supplement_6, November 2021, Page vi78.
57. Tatman P, Wroblewski T, Fringuello A, Scherer S, Foreman W, **Damek D**, Youssef S, Lillehei K, Ormond D, Graner M. Screening of epigenetic compounds in glioma and glioblastoma identifies novel therapeutics for their potential treatment. Poster presentation at the Society of Neuro-oncology Annual Meeting, November 19-21, 2021. *Neuro-Oncology*, Volume 23, Issue Supplement_6, November 2021, Page vi76.
58. Wroblewski T, Tatman P, Fringuello A, Scherer S, Foreman W, **Damek D**, Youssef S, Lillehei K, Ormond D, Graner M. High-throughput screening of epigenetic compounds for the treatment of chordoma identifies potential novel therapeutics. Poster presentation at the Society of Neuro-oncology Annual Meeting, November 19-21, 2021. *Neuro-Oncology*, Volume 23, Issue Supplement_6, November 2021, Page vi84.
59. Wen PY, de Groot JF, Battiste J, Goldlust SA, Garner JS, Friend J, Simpson JA, **Damek D**, Olivero A, Cloughesy TF. Paxalisib in patients with newly diagnosed glioblastoma with unmethylated MGMT promoter status: Final phase 2 study results. *Journal of Clinical Oncology*, Volume 40, Issue 16, Supplement (June 01, 2022), Page 2047. American Society of Clinical Oncology (ASCO) 2022 Annual Meeting, Chicago, IL. June 4-7, 2022.
60. Wen PY, de Groot JF, Battiste J, Goldlust SA, Garner JS, Friend J, Simpson JA, **Damek D**, Olivero A, Cloughesy TF. Pharmacokinetics and pharmacodynamics of paxalisib in newly diagnosed glioblastoma patients with unmethylated MGMT promoter status: final phase 2 study results. ESMO Congress. Paris, France. September 9-13, 2022.
61. Wroblewski TH, Tatman PD, Fringuello AR, Scherer SS, Foreman WB, **Damek DM**, Lillehei K, Jensen RL, Youssef AS, Ormond DR, Graner MW. DNA Methyl Transferase Inhibition in Meningiomas. *J Neurol Surg B Skull Base*. 2022;83(S 01):A040. doi: 10.1055/s-0042-1743634
62. Stortz E, Turin C, Lillehei K, Catel C, **Damek D**, Wierman M. Muscosal-Associated Lymphoid Tissue Lymphoma: A Rare Condition in the Differential Diagnosis of a Parasellar Mass. *J Endocr Soc*. 2022 Nov 1; 6(Suppl 1): A501. Published online 2022 Nov 1. doi: [10.1210/jeendo/bvac150.1042](https://doi.org/10.1210/jeendo/bvac150.1042)